Biogen (BIIB) PT Lowered to $361 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.15 -0.32%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $361.00 (from $381.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Samsonite International SA (1910:HK) (SMSEY) PT Lowered to HK$19.60 at Macquarie
- Maxis Bhd (MAXIS:MK) (MAXSF) PT Raised to MYR3.82 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
